Format

Send to

Choose Destination
See comment in PubMed Commons below
J Neurosci Nurs. 1995 Dec;27(6):344-7.

An open-labelled assessment of adverse effects associated with interferon 1-beta in the treatment of multiple sclerosis.

Author information

  • 1Division of Neurology, University of Missouri-Columbia, School of Medicine, USA.

Abstract

Interferon 1-beta (IFNB) (Betaseron) has been reported to reduce the frequency and severity of exacerbations in relapsing-remitting multiple sclerosis (MS). Adverse effects from this every other day injection are frequent, and most often include injection site reaction or flu-like symptoms. This open-labelled prospective study of MS patients receiving IFNB found that while injection site reactions and flu-like symptoms were seen in 90.0% and 76.7% of patients respectively, only two of 30 patients discontinued therapy for these problems.

PMID:
8770778
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center